JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in patients with newly diagnosed IgA nephropathy.

The frequency of different subsets of CD4(+)CXCR5(+) TFH cells and the levels of serum cytokines were examined in 24 patients with newly diagnosed IgAN before and 8-12 weeks after treatment and in 12 healthy controls (HC). In comparison with HC, significantly higher percentages of CD4(+)CXCR5(+), CD4(+)CXCR5(+)ICOS(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and higher levels of serum IL-17A, IFN-γ, IL-2, IL-10, IL-4 and IL-21 were detected in IgAN patients. The percentages of CD4(+)CXCR5(+) TFH cells were negatively correlated with the values of eGFR and CD4(+)CXCR5(+)PD-1(+) TFH cells were correlated positively with the levels of serum IL-21 and Gd-IgA1 as well as 24h urinary proteins. Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients. A higher frequency of CD4(+)CXCR5(+) TFH cells existed in patients with IgAN and may be associated with the development of IgAN.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app